[ad_1]
Cumulus was selected for innovation showcase and poster presentation. CEO Aman BattyJoin Diversity in Clinical Trials panel hosted by MD, Medidata and Circuit Clinical
Belfast, Northern IrelandWhen bridgewater, new jersey, November 10, 2022 /PR Newswire/ — cumulus neuroscience (Cumulus, the Company), a global digital health company developing multi-domain digital biomarkers for the brain, was honored by the prestigious Life Sciences Forum CNS Summit with its announcement at its annual innovation showcase and real-world reliability was selected for a poster presentation explaining the Digital endpoints of functional neurophysiology. Chief executive officer, Aman BattyMD will also participate in a mainstage panel discussion on clinical trial diversity hosted by Medidata and Circuit Clinical.
“Collaboration and knowledge sharing are at the heart of scientific innovation,” says Dr. Bhatti. “The CNS Summit brings together a united life sciences community around a common goal of accelerating innovation and improving patient experiences and outcomes. Instead, we are honored to publish our own important research and discuss the future of research, diagnosis and treatment of neuropsychological conditions.”
Cumulus Neuroscience will participate in multiple ways at the 2022 CNS Summit.
- innovation showcase: Dr. Batty and Cumulus Founder and Chief Scientific Officer, Brian MurphyPh.D. will present and pitch to pharmaceutical industry leaders in the morning session. Friday, November 18th
- Poster presentation: Cumulus Neuroscience will present a poster presentation. Friday, November 18th Booth #18 on Reliability of Real-World Digital Endpoints in Functional Neurophysiology
- Panel participation: Dr. Bhatti will attend “Live with Kelly and Dana: A 360 View of Diversity in Clinical Trials,” hosted by Medidata and CircuitClinical. February 18th and 12:00 pm.
“Diversity in clinical trials is a key factor in creating a more equitable health environment, but this commitment must be reflected at every stage of the process,” added Dr. Bhatti. . “By joining the voices of industry leaders, we can advance treatments that help a wide range of patients.”
CNS Summit November 17-20 of Boca Raton, Floridaand brings together key pharmaceutical and biotechnology executives dedicated to innovative care in the life sciences.
Cumulus Neuroscience is a leader in advancing clinical trial data, creating tools to enable partners to leverage data, and transforming and accelerating diagnosis and care for patients with central nervous system disorders. For more information on Cumulus Neuroscience, please visit: https://cumulusneuro.com/
About Cumulus Neuroscience
Cumulus Neuroscience is an AI-based, multi-domain platform with a mission to generate the data and insights needed to accelerate the diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers worldwide. Evolving our digital biomarker platform to make better, faster decisions in clinical trials and patient care in neurology and neuropsychiatry, including dementia and Alzheimer’s disease.
Designed to provide the industry standard for real-world measurement of disease progression, Cumulus combines patented technology, in-house expertise and leading industry partnerships to , to obtain large amounts of real-world clinical data repeated over time. Patient home domain – all by certified medical device packages. Together with machine learning (ML) analytics and an extensive real-world database of annotated longitudinal and concordant data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to deliver the best and most accurate CNS treatment outcomes. We provide the most cost-effective assessment.
We are supported by experienced professional investors, DDF/SV Health Investors, LifeArc and Future Fund, and a world-class science and technology advisory board.
For more information
Julie Dietel
FINN Partners
[email protected]
Phone: 978.502.7705
Source Cumulus Neuroscience
[ad_2]
Source link
